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Abstract
Background: Heterologous prime-boost immunization protocols using different gene expression
systems have proven to be successful tools in protecting against various diseases in experimental
animal models. The main reason for using this approach is to exploit the ability of expression
cassettes to prime or boost the immune system in different ways during vaccination procedures.
The purpose of the project was to study the ability of recombinant vaccinia virus (VV) and bacterial
plasmid, both carrying the NS1 gene from tick-borne encephalitis (TBE) virus under the control of
different promoters, to protect mice against lethal challenge using a heterologous prime-boost
vaccination protocol.
Results:  The heterologous prime-boost vaccination protocol, using a VV recombinant and
bacterial plasmid, both containing the NS1 TBE virus protein gene under the control of different
promoters, achieved a high level of protection in mice against lethal challenge with a highly
pathogenic TBE virus strain. No signs of pronounced TBE infection were detected in the surviving
animals.
Conclusion: Heterologous prime-boost vaccination protocols using recombinant VV and bacterial
plasmids could be used for the development of flavivirus vaccines.
Background
Prime-boost immunization protocols using different
expression systems have proven to be successful tools in
protecting experimental animals against various impor-
tant human diseases [1] including tuberculosis [2], AIDS
[3], and hepatitis C [4]. The success of such vaccination
schemes depends upon the efficiency of the expression
systems, of which, recombinant vaccinia virus(VV) and
bacterial plasmid vectors are among the more common
systems studied [6-8]. Moreover, it has been shown that
when at least one component in a prime-boost vaccina-
tion scheme includes a plasmid vector, there is a strong
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response from both pathways of the host immune system
[8]. There is no unique mechanism to account for the effi-
ciency of prime-boost vaccination protocols, but it is well
known that synergy of priming and boosting in the host
using different expression vectors evokes high-avidity
CD4 and CD8 cells [5]. Consequently, several such vacci-
nation protocols are now in human clinical trials [1,6].
Here we present the results of experiments employing the
sequential use of recombinant VV and a bacterial plasmid,
both expressing non-structural protein, NS1, of tick borne
encephalitis (TBE) virus, in protecting mice against lethal
virus infection. It has previously been shown that both
expression systems independently can partially protect
mice against lethal challenge with the highly pathogenic
TBE virus strain but only after repeated revaccinations
[9,10]. Despite the efficiency of commercially available
whole-virion TBE vaccines [11], concerns have been
expressed about the development of non-neutralizing
anti-envelope antibodies that could enhance the infection
[12] if vaccination protocols are not followed, as well as if
individuals are subclinically infected with other flavivi-
ruses or immune compromised. The use of another pro-
tective TBE virus antigen, such as the NS1 non-structural
protein, presented by different expression systems may
help to address these concerns in some circumstances
[9,10,13].
Results and discussion
The results that were obtained with different vaccination
protocols against TBE are presented in Table 1. The com-
bined vaccination scheme of both vectors without the
NS1 gene (VV-WR and pMV100) did not protect mice
against lethal challenge (0% of protection). The recom-
binant vaccinia virus (W-NS1) in combination with the
control plasmid pMV100 protected 20% of challenged
mice, whereas 40% of mice survived that were primed
with control vaccinia vector VV-WR and boosted with the
NS1 gene expressing plasmid pMV45 (the difference is
statistically insignificant). When mice were primed with
the recombinant VV W-NS1 and boosted with plasmid
pMV45, the level of protection significantly increased
(80%).
Detection of anti-NS1 and anti-E (envelope protein) anti-
bodies in vaccinated and challenged mice was carried out
by radioimmuno precipitation analysis (RIPA). The anal-
ysis did not detect anti-NS1 antibodies in the blood of
mice after primary vaccination with the recombinant vac-
cinia virus (W-NS1) (Fig. 1, lanes 5 and 6) but they were
detected after booster vaccination with the recombinant
plasmid pMV45 (Fig. 1, lanes 7 and 8). Anti-NS1 antibod-
ies were also detected in vaccinated animals after subse-
quent challenge with the TBE virus (Fig. 2, lanes 7 and 8).
However, sera from surviving mice did not contain anti-
bodies against TBE virus E protein, suggesting that pro-
nounced virus infection was not present in vaccinated and
challenged animals (Fig. 2, lanes 7 and 8). In separate
experiments, neither the W-NS1 recombinant nor the
pMV45 plasmid, introduced alone, induced detectable
amount of anti-NS1 antibodies in mice (data not
shown).)Antibodies against NS1 protein could protect
mice against the lethal challenge with homologous flaviv-
iruses including TBE virus [15,16]. Involvement of Th1
immune response in protection elicited by the combined
vaccination with two recombinant systems used in this
study can not be excluded.
These studies are the first to demonstrate that the com-
bined use of well-characterised expression systems
employing recombinant vaccinia viruses and bacterial
plasmids (DNA vaccination) can protect experimental
animals against a lethal flavivirus infection. Both these
expression systems could be rapidly deployed to provide
simple methods of constructing vaccines against several
dangerous emerging diseases that have caused severe
Table 1: Protection of experimental animals against TBE virus in mice immunized with a vaccinia virus recombinant and a bacterial 
plasmid, both carrying the gene for the NS1 non-structural TBE virus protein
Group number Primary immunization Booster immunization surviving/infected animals (% of 
survivers ± SE)
1 VV W-NS1 pMV45 8/10 (80 ± 13%)
2 VV W-NS1 pMV100 2/10 (20 ± 13%)
3 VV WR pMV45 4/10 (40 ± 15%)
4 VV WR pMV100 0/10 (0%)
5 None None 0/10 (0%)
*- Balb/c mice were primed either with vaccinia viruses WR or W-NS1, boosted with bacterial plasmids pMV45 or pMV100 and challenged 
intraperitoneally with the TBE virus (Absettarov strain, 100 LD50) as described in the Materials and Methods section. All the animals were 
monitored for 3 weeks after challenge with TBE virus. Standard error (SE) of a percent value was determined by the equation: SE = Square root of 
p × (100-p)/n, where p is a percent value and n is a number of animals used. Significance between two percent values (with probability 0.95): t = P1-
P2/square root of SE12 + SE22 ≥ 2.0 [14].BMC Microbiology 2005, 5:45 http://www.biomedcentral.com/1471-2180/5/45
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threats to public health in many different countries during
the past few years.
In our experiments we used the poxvirus recombinant
based on the WR laboratory strain which replicates better
in cell cultures and mice than other strains of VV.
Although more convenient for our experiments, this
strain could not be used directly for vaccination of
humans due to its relatively high virulence. However, it
can easily be used to prepare the analogous recombinants
on the basis of vaccinal VV strains (Lister, Copenhagen,
Praha and others) by inserting the NS1 gene into their tk
gene. These strains have been broadly used for immuniza-
tion against smallpox in the past.
Although vaccination against smallpox was stopped many
years ago, it could be reinstated if a bioterrorist attack is
thought to be imminent. Indeed, the USA, UK and several
other European countries have stockpiled traditional vac-
cines as a precaution against such an event. However, it
could be argued that it is more sensible to vaccinate
humans, not with the traditional vaccinal VV strains, but
with their recombinants carrying genes encoding protec-
tive antigens from other pathogens, inserted into the VV
thymidine kinase (tk) gene [17]. Despite the fact that VV
tk- recombinants have never been used for vaccinations
against smallpox in the past, there are many reasons that
they could protect against the disease as with the original
VV strains: 1) they have the same antigenic structure; 2) a
tk- recombinant constructed on the basis of the Lister
strain that expressed hepatitis B virus HBsAg antigen [18]
could efficiently replicate in calf skin, which enabled the
production of dermal recombinant vaccine against hepa-
titis B and to conduct human trials [19]; 3) this recom-
binant induced a specific reaction in rabbit, calf and
human skin and evoked neutralizing antibodies against
orthopoxviruses [19,20]. Such recombinants would have
substantial advantages over traditional VV. Not only
would they possess reduced neurovirulence due to
destruction of the tk gene [18,21,22] (residual neuroviru-
lence of VV is a main cause of severe postvaccinal compli-
cations), but they would also be able to offer protection
against smallpox and another pathogen. For instance, VV
recombinants expressing protective antigens of TBE virus,
including NS1 protein, could be used in TBE endemic
regions. In this case, prime-boost vaccination protocols,
which include recombinant bacterial plasmids as a
booster, could provide protection against TBE without
raising concerns that pre-existing immunity to vaccinia
virus could reduce the immune response to TBE viral pro-
teins. Such strategies could also help to cut the cost of the
vaccination procedure, thus making them attractive pub-
lic health interventions.
Study of mouse sera in RIPA with the TBE virus infected and  radioactive labeled SPEV cell extracts Figure 1
Study of mouse sera in RIPA with the TBE virus 
infected and radioactive labeled SPEV cell extracts. 
Lanes 1 and 2 – serum from intact mice; lanes 3 and 4 – 
mouse anti-NS1 sera [9]; lanes 5 and 6 – pooled sera of mice 
vaccinated with the vaccinia virus recombinant (W-NS1); 
lanes 7 and 8 – pooled sera from mice primed with W-NS1 
after booster vaccination with pMV45. Odd lanes: samples 
were boiled before SDS electrophoresis to detect NS1-mon-
omers; even lanes: samples were not boiled before electro-
phoresis to detect NS1-dimers. The position of monomers 
(mNS1) and dimers (dNS1) of the NS1 protein are marked 
with arrows.
Study of mouse sera in RIPA with the TBE virus infected and  radioactive labeled SPEV cell extracts Figure 2
Study of mouse sera in RIPA with the TBE virus 
infected and radioactive labeled SPEV cell extracts. 
Lanes 1 and 2 – serum from intact mice; lanes 3 and 4 – anti-
E protein Mab; lanes 5 and 6 – mouse anti-NS1 serum [9]; 
lanes 7 and 8 – pooled sera from mice vaccinated with W-
NS1 and pMV45 which survived after the challenge with the 
TBE virus. Odd lanes: samples were boiled before SDS elec-
trophoresis; even lanes: samples were not boiled before elec-
trophoresis. The position of E protein, monomers (mNS1) 
and dimers (dNS1) of the NS1 protein are marked with 
arrows.BMC Microbiology 2005, 5:45 http://www.biomedcentral.com/1471-2180/5/45
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Conclusion
A combined prime-boost vaccination protocol, including
a VV recombinant and a bacterial plasmid, both contain-
ing the NS1 non-structural TBE virus protein gene, gave
high levels of protection in mice against lethal challenge
with the highly pathogenic TBE virus strain. This prime-
boost vaccination protocol could be employed in the
development of novel flavivirus vaccines for use in TBE




The TBE virus strains Absettarov and Sophyin were
obtained from the collection of viruses at the Chumakov
Institute of Poliomyelitis and Viral Encephalitis RAMS, as
mouse brain suspensions with known LD50 titres. The
recombinant bacterial plasmid pMV45, carrying the gene
for the non-structural TBE virus protein NS1 (Western
subtype Neudorfl), under the control of the cytomegalo-
virus immediate early promoter has been described earlier
[13]. Plasmid pMV100, carrying the cytomegalovirus
expression cassette without an insert was used as a nega-
tive control [13]. Plasmid preparations were performed
according to EndoFree Plasmid Mega protocol (QIAGEN
Inc., USA). The construction and characterisation of the
VV recombinant (W-NS1), expressing the TBE virus non-
structural NS1 protein gene, inserted into the tk  gene
under the control of the synthetic early-late poxvirus pro-
moter has been described previously [10]. The recom-
binant and the parental vaccinia virus strain (WR strain)
were propagated and titrated in the CV1 simian kidney
cells.
Animal experiments
Male Balb/c mice weighing 10–12 g were used. The VV
recombinant and the negative control virus were injected
intraperitoneally as doses of 107 PFU/mouse. The bacte-
rial plasmids were introduced intramuscularly as 50 µg
doses per mouse. The interval between vaccinations was 2
weeks. Two weeks after the last vaccination, mice were
challenged intraperitoneally with 100 LD50 of the highly
virulent TBE virus strain Absettarov (Western subtype)
and monitored for 3 weeks. Not less then 5 mice from
each group were bled before the challenge and their sera
were pooled. The survivors from groups vaccinated with
W-NS1 and pMV45 were also bled and their sera pooled
for analysis. All experiments involving live animals were
conducted according to International guidelines on the
ethical use of animals.
Analysis by radioimmune precipitation (RIPA)
Continuous cultures of porcine embryo kidney cells
(SPEV) were infected with 1 PFU/cell of TBE virus (strain
Sophyin). Thirty-six hours after infection Earl's 199
medium with 0.1% of human serum albumin (v/v) was
substituted for Earl's salt solution. A 14C-labelled amino
acid mixture (Amersham, USA) was added at a concentra-
tion of 2.5 µCi/ml and the cell sheets were harvested 12
hours later, lysed in immune precipitation buffer fol-
lowed by three rounds of freezing and thawing as
described previously [23].
The RIPA procedure was carried out for detection of anti-
bodies against TBE virus NS1 and envelope E proteins
using Protein A -Sepharose with subsequent electrophore-
sis of precipitates in 10% SDS-PAGE and exposure to X-
ray film as described earlier [9,23]. E and NS1 protein
monomers migrate closely on 10% SDS PAGE gel. In
order to identify them on a gel, we used the boiled and
unboiled variants of samples for electrophoresis. The
unboiled samples of NS1 protein contain NS1 dimers.
Boiling does not influence the electrophoretic mobility of
E protein. Mouse anti-NS1 serum was obtained by vacci-
nation of animals with pMV45 [9]. Monoclonal antibody
(Mab) against TBE virus E protein was a kind gift of Dr. A.
Kushch (Ivanovsky Institute of Virology RAMS, Moscow,
Russia).
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